265 related articles for article (PubMed ID: 26682574)
1. The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.
Tipton AF; Tarash I; McGuire B; Charles A; Pradhan AA
Cephalalgia; 2016 Oct; 36(11):1048-1056. PubMed ID: 26682574
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Ben Aissa M; Tipton AF; Bertels Z; Gandhi R; Moye LS; Novack M; Bennett BM; Wang Y; Litosh V; Lee SH; Gaisina IN; Thatcher GR; Pradhan AA
Cephalalgia; 2018 Jul; 38(8):1471-1484. PubMed ID: 29022756
[TBL] [Abstract][Full Text] [Related]
3. Animal Model of Chronic Migraine-Associated Pain.
Moye LS; Pradhan AAA
Curr Protoc Neurosci; 2017 Jul; 80():9.60.1-9.60.9. PubMed ID: 28678396
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel model of chronic migraine.
Pradhan AA; Smith ML; McGuire B; Tarash I; Evans CJ; Charles A
Pain; 2014 Feb; 155(2):269-274. PubMed ID: 24121068
[TBL] [Abstract][Full Text] [Related]
5. A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Kopruszinski CM; Navratilova E; Swiokla J; Dodick DW; Chessell IP; Porreca F
Cephalalgia; 2021 Mar; 41(3):305-317. PubMed ID: 32985222
[TBL] [Abstract][Full Text] [Related]
6. Utility of different outcome measures for the nitroglycerin model of migraine in mice.
Farkas S; Bölcskei K; Markovics A; Varga A; Kis-Varga Á; Kormos V; Gaszner B; Horváth C; Tuka B; Tajti J; Helyes Z
J Pharmacol Toxicol Methods; 2016; 77():33-44. PubMed ID: 26456070
[TBL] [Abstract][Full Text] [Related]
7. Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation.
Long T; He W; Pan Q; Zhang S; Zhang Y; Liu C; Liu Q; Qin G; Chen L; Zhou J
J Neuroinflammation; 2018 Aug; 15(1):245. PubMed ID: 30165876
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats.
Sufka KJ; Staszko SM; Johnson AP; Davis ME; Davis RE; Smitherman TA
J Headache Pain; 2016; 17():40. PubMed ID: 27093871
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap.
Cady R; Nett R; Dexter K; Freitag F; Beach ME; Manley HR
Headache; 2014 Jan; 54(1):80-93. PubMed ID: 24020994
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A; Gennings C; Cady R
Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
[TBL] [Abstract][Full Text] [Related]
12. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
13. Effects of systemic inhibitors of acid-sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine.
Verkest C; Piquet E; Diochot S; Dauvois M; Lanteri-Minet M; Lingueglia E; Baron A
Br J Pharmacol; 2018 Nov; 175(21):4154-4166. PubMed ID: 30079481
[TBL] [Abstract][Full Text] [Related]
14. Low-dose sodium valproate versus low-dose propranolol in prophylaxis of common migraine headache: A randomized, prospective, parallel, open-label study.
Dakhale GN; Sharma VS; Thakre MN; Kalikar M
Indian J Pharmacol; 2019; 51(4):255-262. PubMed ID: 31571712
[TBL] [Abstract][Full Text] [Related]
15. No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine.
Ernstsen C; Christensen SL; Olesen J; Kristensen DM
Cephalalgia; 2021 Mar; 41(3):329-339. PubMed ID: 33059476
[TBL] [Abstract][Full Text] [Related]
16. δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.
Pradhan AA; Smith ML; Zyuzin J; Charles A
Br J Pharmacol; 2014 May; 171(9):2375-84. PubMed ID: 24467301
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine.
Ghelardini C; Galeotti N; Grazioli I; Uslenghi C
J Pain; 2004 Oct; 5(8):413-9. PubMed ID: 15501422
[TBL] [Abstract][Full Text] [Related]
18. P2X7R-mediated autophagic impairment contributes to central sensitization in a chronic migraine model with recurrent nitroglycerin stimulation in mice.
Jiang L; Zhang Y; Jing F; Long T; Qin G; Zhang D; Chen L; Zhou J
J Neuroinflammation; 2021 Jan; 18(1):5. PubMed ID: 33402188
[TBL] [Abstract][Full Text] [Related]
19. Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.
Knapp L; Szita B; Kocsis K; Vécsei L; Toldi J
Drug Des Devel Ther; 2017; 11():27-34. PubMed ID: 28053504
[TBL] [Abstract][Full Text] [Related]
20. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.
Akerman S; Karsan N; Bose P; Hoffmann JR; Holland PR; Romero-Reyes M; Goadsby PJ
Brain; 2019 Jan; 142(1):103-119. PubMed ID: 30596910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
